文献速递核素与放射性配体治疗肿瘤 PET/CT

[177Lu]Lu-PSMA-I&T治疗中参考多时间点剂量学方案对单时间点剂量学有效性的影响

Impact of the Reference Multiple-Time-Point Dosimetry Protocol on the Validity of Single-Time-Point Dosimetry for [177Lu]Lu-PSMA-I&T Therapy.
PubMed 文献 · J Nucl Med · 2024-08-01

该研究基于7例接受[177Lu]Lu-PSMA-I&T治疗患者的全身SPECT/CT数据(注射后24、48、72、168小时采集),比较不同参考多时间点方案下三种群体单时间点剂量学方法的误差与最佳成像时间。结果显示单时间点剂量学平均偏差可小于10%或可行,但偏差和最佳时间点依赖于所选参考方案,48小时或可作为折中时间点。

要点

  • 单时间点剂量学平均偏差小于10%或可行,但偏差取决于所选参考方案。
  • 根据本患者队列,注射后48小时或可作为病灶和危机器官单时间点剂量学的折中时间点。
  • 不同参考模型间病灶、肾脏和涎腺吸收剂量估计最大差异分别为-44%、-19%和-28%。

核心结论

  • 单时间点剂量学用于[177Lu]Lu-PSMA治疗有希望促进剂量学整合进入临床常规。
  • 根据本患者队列,注射后48小时或可作为病灶和危机器官单时间点剂量学的折中时间点。
  • 本分析结果表明,需要统一的剂量学金标准以实现可靠且可比较的单时间点剂量学。

研究设计与样本

  • 纳入7例接受[177Lu]Lu-PSMA-I&T治疗的患者,给药活度为7.4-8.9 GBq。
  • 全身SPECT/CT扫描安排在注射后24、48、72和168小时。
  • 在SPECT/CT数据中勾画60个病灶、14个肾脏和10个涎腺。
  • 依据拟合优度分析(变异系数、误差平方和)将单指数和双指数两种曲线模型拟合至多时间点数据。
  • 比较三种基于群体的单时间点方法:Hänscheid等发表的方法、Jackson等发表的方法、以及在单指数或双指数曲线模型中使用基于群体的有效半衰期的方法。

主要发现

  • 拟合优度参数显示,单指数函数和具有共享群体参数与物理尾部的双指数函数是合理的参考模型。
  • 比较两种参考模型时,病灶、肾脏和涎腺吸收剂量估计的最大差异分别为-44%、-19%和-28%。
  • 单时间点剂量学与多时间点剂量学的平均偏差小于10%或可行,但该偏差和最佳成像时间点依赖于所选参考方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Internal dosimetry supports safe and effective patient management during radionuclide therapy. Yet, it is associated with high clinical workload, costs, and patient burden, as patient scans at multiple time points (MTPs) must be acquired. Dosimetry based on imaging at a single time point (STP) has continuously gained popularity. However, MTP protocols, used as a reference to judge the validity of STP dosimetry, differ depending on local requirements and deviate from the unknown patient-specific ground truth pharmacokinetics. The aim of this study was to compare the error and optimum time point for different STP approaches using different reference MTP protocols. Methods: Whole-body SPECT/CT scans of 7 patients (7.4-8.9 GBq of [177Lu]Lu-PSMA-I&T) were scheduled at 24, 48, 72, and 168 h after injection. Sixty lesions, 14 kidneys, and 10 submandibular glands were delineated in the SPECT/CT data. Two curve models, that is, a mono- and a biexponential model, were fitted to the MTP data, in accordance with goodness-of-fit analysis (coefficients of variation, sum of squared errors). Three population-based STP approaches were compared: one method published by Hänscheid et al., one by Jackson et al., and one using population-based effective half-lives in the mono- or biexponential curve models. Percentage differences between STP and MTP dosimetry were evaluated. Results: Goodness-of-fit parameters show that a monoexponential function and a biexponential function with shared population-based parameters and physical tail are reasonable reference models. When comparing both reference models, we observed maximum differences of -44%, -19%, and -28% in the estimated absorbed doses for lesions, kidneys, and salivary glands, respectively. STP dosimetry with an average deviation of less than 10% from MTP dosimetry may be feasible; however, this deviation and the optimum imaging time point showed a dependence on the chosen reference protocol. Conclusion: STP dosimetry for [177Lu]Lu-PSMA therapy is promising to boost the integration of dosimetry into clinical routine. According to our patient cohort, 48 h after injection may be regarded as a compromise for STP dosimetry for lesions and at-risk organs. The results from this analysis show that a common gold standard for dosimetry is desirable to allow for reliable and comparable STP dosimetry.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Resch S, Ziegler SI, Sheikh G, et al. Impact of the Reference Multiple-Time-Point Dosimetry Protocol on the Validity of Single-Time-Point Dosimetry for [177Lu]Lu-PSMA-I&T Therapy. J Nucl Med. 2024. PMID: 38936975. doi:10.2967/jnumed.123.266871

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。